Tech Company Financing Transactions
Cyteir Therapeutics Funding Round
On 3/9/2018, Cyteir Therapeutics received $29 million in Series B funding from Venrock, Celgene and DROIA.
Transaction Overview
Company Name
Announced On
3/9/2018
Transaction Type
Venture Equity
Amount
$29,000,000
Round
Series B
Investors
Venrock (Lead Investor) (Racquel Bracken)
Celgene (Markus Renschler)
DROIA (Bart Hooland)
Lightstone Ventures (Jean George)
Proceeds Purpose
Proceeds from the financing will be used to progress the company's lead program focused on selective, small-molecule inhibitors of the protein RAD51 for use in oncology, with the goal of entering initial clinical trials in 2019. Proceeds will also be used to accelerate preclinical development of synthetic lethality therapeutics for autoimmune diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
128 Spring St. Building A 510
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
DNA damage and genomic instability are hallmarks of cancer and autoimmune diseases. This makes the disease-causing cells highly sensitive to drugs that target specific DNA repair factors. This is termed synthetic lethality.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Markus Renschler
Chief Scientific Officer
Paul Secrist
Vice President
Jean-Marc Lapierre
Vice President
Thomas O'Shea
VP - Bus. Development
Andrew Gengos
VP - Operations
Susan Doleman
VP - R & D
Judson Englert
VP - R & D
Barbara Wan
Browse more venture capital transactions:
Prev: 3/9/2018: PolicyPal venture capital transaction
Next: 3/9/2018: Kixeye venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs